|
Ciliary Motility Disorders
|
0.100 |
GeneticVariation
|
group |
CLINVAR |
|
|
|
|
Ciliary Motility Disorders
|
0.100 |
CausalMutation
|
group |
CLINVAR |
|
|
|
|
CILIARY DYSKINESIA, PRIMARY, 7 (disorder)
|
0.100 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Cell division cycle associated 7 like predicts unfavorable prognosis and promotes invasion in glioma.
|
30389317 |
2019 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Association analysis identifies 65 new breast cancer risk loci.
|
29059683 |
2017 |
|
Viral Load result
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial.
|
31219150 |
2019 |
|
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial.
|
31219150 |
2019 |
|
HIV-1, RESISTANCE TO
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial.
|
31219150 |
2019 |
|
ACQUIRED IMMUNODEFICIENCY SYNDROME, PROGRESSION TO
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial.
|
31219150 |
2019 |
|
AIDS, PROGRESSION TO
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial.
|
31219150 |
2019 |
|
Liver carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Collectively, these findings show that CDCA7L plays a role in promoting the development of HCC and may constitute a potential therapeutic target in HCC.
|
24141559 |
2013 |
|
Multiple Myeloma
|
0.110 |
GeneticVariation
|
disease |
GWASDB |
Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk.
|
22120009 |
2011 |
|
Multiple Myeloma
|
0.110 |
GeneticVariation
|
disease |
GWASDB |
Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk.
|
23955597 |
2013 |
|
Neoplasm Metastasis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Immunohistochemical studies indicate tumor-specific JPO2 expression in human medulloblastoma, and an association of JPO2 expression with metastatic tumors.
|
15994933 |
2005 |
|
Multiple Endocrine Neoplasia Type 1
|
0.010 |
Biomarker
|
disease |
BEFREE |
In a CpG island methylator phenotype analysis, 3 genes were identified and confirmed to have downregulated gene expression: secreted frizzle-related protein 5 (SFRP5) in sporadic NFPanNETs and cell division cycle-associated 7-like (CDCA7L) and RNA binding motif 47 (RBM47) in MEN1-related NFPanNETs.
|
30620390 |
2019 |
|
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
In an in vivo model, subcutaneous transplantation of the tumor in nude mice showed that overexpression of CDCA7L can accelerate the tumor growth rate.
|
24141559 |
2013 |
|
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Moreover, the current retrospective cohort study indicated that high CDCA7L expression was associated with tumor size, WHO grade, adjuvant therapy and recurrence, as well as the poor overall survival (OS) and recurrence-free survival (RFS) in glioma patients.
|
30389317 |
2019 |
|
Recurrent tumor
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Moreover, the relationship of CDCA7L expression with the clinicopathological characteristics in glioma patients, including age, gender, tumor size, cystic change, Karnofsky performance scale (KPS) score, tumor location, extent of resection, WHO grade, adjuvant therapy and tumor recurrence, was analyzed in this study.
|
30389317 |
2019 |
|
Glioma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Our results suggested that CDCA7L expression was up-regulated in different glioma types, including glioblastoma, oligodendroglioma, diffuse astrocytoma and anaplastic astrocytoma.
|
30389317 |
2019 |
|
Adult Anaplastic Astrocytoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our results suggested that CDCA7L expression was up-regulated in different glioma types, including glioblastoma, oligodendroglioma, diffuse astrocytoma and anaplastic astrocytoma.
|
30389317 |
2019 |
|
Anaplastic astrocytoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our results suggested that CDCA7L expression was up-regulated in different glioma types, including glioblastoma, oligodendroglioma, diffuse astrocytoma and anaplastic astrocytoma.
|
30389317 |
2019 |
|
Grade III Childhood Astrocytoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our results suggested that CDCA7L expression was up-regulated in different glioma types, including glioblastoma, oligodendroglioma, diffuse astrocytoma and anaplastic astrocytoma.
|
30389317 |
2019 |
|
social stress
|
0.010 |
Biomarker
|
disease |
BEFREE |
Over the last few decades, several regulatory pathways of MAO-A consisting of Kruppel like factor 11 (KLF11), Sirtuin1, Ring finger protein in neural stem cells (RINES), and Cell division cycle associated 7-like protein (R1) have been identified, and the influence of social stress on these regulatory factors evaluated.
|
29163009 |
2017 |
|
Myocardial Infarction
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Overall, this is the first study, which presented an advanced platform for the gene therapy that reverses adverse cardiac remodeling after MI with a HR1 gene delivered by a bioreducible dendrimer polymer in the cardiac ECM.
|
27174688 |
2016 |
|
Medulloblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Reporter gene and/or gel shift assays confirmed direct repression of Tsp-1 transcription by Myc and also identified JPO2, a Myc interactor associated with metastatic medulloblastoma, as a cofactor in Myc-mediated Tsp-1 repression.
|
20876797 |
2010 |